242P Effects of nal-IRI (MM-398) ± 5-fluorouracil on quality of life (QoL) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine based therapy: Results from NAPOLI-1

Pancreatic ductal adenocarcinoma (PDAC) most commonly affects the head of the pancreas. This condition has a dismal prognosis. Patients with early disease may be candidates for pancreaticoduodenectomy (PD). This is a high-risk operation which is associated with considerable morbidity. Whilst perioperative mortality rates have fallen in recent times, the risk remains significant and long-term survival is poor, even in those who make an uncomplicated recovery. Furthermore, PD is known to affect quality of life (QoL) negatively. Most studies suggest it takes up to six months before a patient’s QoL returns to baseline. This is a considerable amount of time for a patient who is unlikely to achieve long-term survival. This short review discusses the recent literature surrounding mortality rates, long-term survival and QoL following PD for PDAC. A comprehensive understanding of these topics will allow clinicians and patients to consider the risks and benefits before surgical resection is considered.

Download Full-text

183 - Prospective, Randomized, Double Blind Clinical Trial of Celiac Plexus Neurolysis and Celiac Ganglia Neurolysis for Pancreatic Ductal Adenocarcinoma: Impact of Total Ganglia Volume on Pain, Quality of Life and Survival

Gastroenterology ◽

10.1016/s0016-5085(18)30626-7 ◽

2018 ◽

Vol 154 (6) ◽

pp. S-47

Author(s):

Michael J. Levy ◽

Ferga C. Gleeson ◽

Mark Topazian ◽

Larissa L. Fujii-Lau ◽

Felicity Enders ◽

...

Keyword(s):

Quality Of Life ◽

Clinical Trial ◽

Pancreatic Ductal Adenocarcinoma ◽

Celiac Plexus ◽

Ductal Adenocarcinoma ◽

Double Blind ◽

Double Blind Clinical Trial

Download Full-text

Palliative Resection of Pancreatic Adenocarcinoma

HPB Surgery ◽

10.1155/1995/54241 ◽

1995 ◽

Vol 8 (3) ◽

pp. 181-183 ◽

Cited By ~ 1

Author(s):

C. D. Johnson

Keyword(s):

Quality Of Life ◽

Liver Metastases ◽

Pancreatic Ductal Adenocarcinoma ◽

Pancreatic Adenocarcinoma ◽

Pancreatic Resection ◽

Postal Questionnaire ◽

Palliative Resection ◽

Ductal Adenocarcinoma ◽

Adenocarcinoma Of The Pancreas

A survey was carried out by postal questionnaire of the attitudes of British surgeons to pancreatic resection as palliation for ductal adenocarcinoma of the pancreas. Replies from 24 surgeons related to experience in over 700 resections. The incidence of estimated residual local disease after resection was median 12.5 percent, range 0–35 percent. Half(12) of the surgeons felt that pancreatic resection with residual macroscopic disease was justified. Only 3 (12.5 percent) surgeons accepted that palliative resection in the presence of liver metastases was sometimes justifiable. Further evidence is required of improved quality of life after resection before the majority of surgeons will accept palliative resection in the management of pancreatic ductal adenocarcinoma.

Download Full-text